Drug intelligence / Profile preview

naveglitazar

Development stage: Phase 2
Lead developer: Zydus Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Naveglitazar is an investigational small molecule drug that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist, targeting both PPAR alpha and PPAR gamma subtypes. Its mechanism of action involves modulating lipid and glucose metabolism, aiming to improve insulin sensitivity and reduce dyslipidemia. Naveglitazar was studied for the treatment of cardiovascular disease, dyslipidemia, and type 2 diabetes. However, further development of naveglitazar has been stopped[7].

Other names: S-Bristol-Myers Squibb-obesity

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on naveglitazar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naveglitazar.

Explore the full profile